RSS feed

Publications by Idar Lygren

86 publications found

Original articles

Therkelsen SP, Hetland G, Lyberg T, Lygren I, Johnson E (2016)
Cytokine Levels After Consumption of a Medicinal Agaricus blazei Murill-Based Mushroom Extract, AndoSan^™ , in Patients with Crohn's Disease and Ulcerative Colitis in a Randomized Single-Blinded Placebo-Controlled Study
Scand J Immunol, 84 (6), 323-331
DOI 10.1111/sji.12476, PubMed 27588816

Therkelsen SP, Hetland G, Lyberg T, Lygren I, Johnson E (2016)
Effect of the Medicinal Agaricus blazei Murill-Based Mushroom Extract, AndoSanTM, on Symptoms, Fatigue and Quality of Life in Patients with Crohn's Disease in a Randomized Single-Blinded Placebo Controlled Study
PLoS One, 11 (7), e0159288
DOI 10.1371/journal.pone.0159288, PubMed 27415795

Therkelsen SP, Hetland G, Lyberg T, Lygren I, Johnson E (2016)
Effect of a Medicinal Agaricus blazei Murill-Based Mushroom Extract, AndoSan™, on Symptoms, Fatigue and Quality of Life in Patients with Ulcerative Colitis in a Randomized Single-Blinded Placebo Controlled Study
PLoS One, 11 (3), e0150191
DOI 10.1371/journal.pone.0150191, PubMed 26933886

De Vos M, Louis EJ, Jahnsen J, Vandervoort JG, Noman M, Dewit O, Dʼhaens GR, Franchimont D, Baert FJ, Torp RA, Henriksen M, Potvin PM, Van Hootegem PP, Hindryckx PM, Moreels TG, Collard A, Karlsen LN, Kittang E, Lambrecht G, Grimstad T, Koch J, Lygren I, Coche JC, Mana F, Van Gossum A et al. (2013)
Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy
Inflamm Bowel Dis, 19 (10), 2111-7
DOI 10.1097/MIB.0b013e31829b2a37, PubMed 23883959

Trøseid M, Lind A, Nowak P, Barqasho B, Heger B, Lygren I, Pedersen KK, Kanda T, Funaoka H, Damås JK, Kvale D (2012)
Circulating levels of HMGB1 are correlated strongly with MD2 in HIV-infection: possible implication for TLR4-signalling and chronic immune activation
Innate Immun, 19 (3), 290-7
DOI 10.1177/1753425912461042, PubMed 23070967

Høivik ML, Bernklev T, Solberg IC, Cvancarova M, Lygren I, Jahnsen J, Moum B, IBSEN Study Group (2011)
Patients with Crohn's disease experience reduced general health and vitality in the chronic stage: ten-year results from the IBSEN study
J Crohns Colitis, 6 (4), 441-53
DOI 10.1016/j.crohns.2011.10.001, PubMed 22398064

Førland DT, Johnson E, Saetre L, Lyberg T, Lygren I, Hetland G (2011)
Effect of an extract based on the medicinal mushroom Agaricus blazei Murill on expression of cytokines and calprotectin in patients with ulcerative colitis and Crohn's disease
Scand J Immunol, 73 (1), 66-75
DOI 10.1111/j.1365-3083.2010.02477.x, PubMed 21129005

Kringen MK, Narum S, Lygren I, Seljeflot I, Sandset PM, Trøseid AM, Johansen PW, Brørs O, Holthe MR (2010)
Reduced platelet function and role of drugs in acute gastrointestinal bleeding
Basic Clin Pharmacol Toxicol, 108 (3), 194-201
DOI 10.1111/j.1742-7843.2010.00643.x, PubMed 21118353

Søberg T, Hofstad B, Sandvik L, Johansen M, Lygren I (2010)
[Risk factors for peptic ulcer bleeding]
Tidsskr Nor Laegeforen, 130 (11), 1135-9
DOI 10.4045/tidsskr.08.0693, PubMed 20531499

Solberg IC, Lygren I, Cvancarova M, Jahnsen J, Stray N, Sauar J, Schreiber S, Moum B, Vatn MH, IBSEN Study Group (2009)
Predictive value of serologic markers in a population-based Norwegian cohort with inflammatory bowel disease
Inflamm Bowel Dis, 15 (3), 406-14
DOI 10.1002/ibd.20781, PubMed 19009607

Solberg IC, Lygren I, Jahnsen J, Aadland E, Høie O, Cvancarova M, Bernklev T, Henriksen M, Sauar J, Vatn MH, Moum B, IBSEN Study Group (2009)
Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study)
Scand J Gastroenterol, 44 (4), 431-40
DOI 10.1080/00365520802600961, PubMed 19101844

Bengtson MB, Solberg C, Aamodt G, Sauar J, Jahnsen J, Moum B, Lygren I, Vatn MH, IBSEN study group (2008)
Familial aggregation in Crohn's disease and ulcerative colitis in a Norwegian population-based cohort followed for ten years
J Crohns Colitis, 3 (2), 92-9
DOI 10.1016/j.crohns.2008.11.002, PubMed 21172251

Henriksen M, Jahnsen J, Lygren I, Stray N, Sauar J, Vatn MH, Moum B, IBSEN Study Group (2008)
C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study
Gut, 57 (11), 1518-23
DOI 10.1136/gut.2007.146357, PubMed 18566104

Negaard A, Sandvik L, Berstad AE, Paulsen V, Lygren I, Borthne A, Klow NE (2008)
MRI of the small bowel with oral contrast or nasojejunal intubation in Crohn's disease: randomized comparison of patient acceptance
Scand J Gastroenterol, 43 (1), 44-51
DOI 10.1080/00365520701494813, PubMed 18158695

Larssen L, Moger T, Bjørnbeth BA, Lygren I, Kløw NE (2008)
Transcatheter arterial embolization in the management of bleeding duodenal ulcers: a 5.5-year retrospective study of treatment and outcome
Scand J Gastroenterol, 43 (2), 217-22
DOI 10.1080/00365520701676443, PubMed 18224566

Solberg IC, Vatn MH, Høie O, Stray N, Sauar J, Jahnsen J, Moum B, Lygren I, IBSEN Study Group (2007)
Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study
Clin Gastroenterol Hepatol, 5 (12), 1430-8
DOI 10.1016/j.cgh.2007.09.002, PubMed 18054751

Henriksen M, Jahnsen J, Lygren I, Vatn MH, Moum B, IBSEN Study Group (2007)
Are there any differences in phenotype or disease course between familial and sporadic cases of inflammatory bowel disease? Results of a population-based follow-up study
Am J Gastroenterol, 102 (9), 1955-63
DOI 10.1111/j.1572-0241.2007.01368.x, PubMed 17573793

Negaard A, Paulsen V, Sandvik L, Berstad AE, Borthne A, Try K, Lygren I, Storaas T, Klow NE (2007)
A prospective randomized comparison between two MRI studies of the small bowel in Crohn's disease, the oral contrast method and MR enteroclysis
Eur Radiol, 17 (9), 2294-301
DOI 10.1007/s00330-007-0648-4, PubMed 17483955

Henriksen M, Jahnsen J, Lygren I, Aadland E, Schulz T, Vatn MH, Moum B, Ibsen Study Group (2007)
Clinical course in Crohn's disease: results of a five-year population-based follow-up study (the IBSEN study)
Scand J Gastroenterol, 42 (5), 602-10
DOI 10.1080/00365520601076124, PubMed 17454881

Knudsen GP, Pedersen J, Klingenberg O, Lygren I, Ørstavik KH (2007)
Increased skewing of X chromosome inactivation with age in both blood and buccal cells
Cytogenet Genome Res, 116 (1-2), 24-8
DOI 10.1159/000097414, PubMed 17268174

Henriksen M, Jahnsen J, Lygren I, Sauar J, Schulz T, Stray N, Vatn MH, Moum B, Ibsen Study Group (2006)
Change of diagnosis during the first five years after onset of inflammatory bowel disease: results of a prospective follow-up study (the IBSEN Study)
Scand J Gastroenterol, 41 (9), 1037-43
DOI 10.1080/00365520600554527, PubMed 16938716

Henriksen M, Jahnsen J, Lygren I, Sauar J, Kjellevold Ø, Schulz T, Vatn MH, Moum B, IBSEN Study Group (2006)
Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study)
Inflamm Bowel Dis, 12 (7), 543-50
DOI 10.1097/01.MIB.0000225339.91484.fc, PubMed 16804390

Bernklev T, Jahnsen J, Henriksen M, Lygren I, Aadland E, Sauar J, Schulz T, Stray N, Vatn M, Moum B (2006)
Relationship between sick leave, unemployment, disability, and health-related quality of life in patients with inflammatory bowel disease
Inflamm Bowel Dis, 12 (5), 402-12
DOI 10.1097/01.MIB.0000218762.61217.4a, PubMed 16670530

Bernklev T, Jahnsen J, Schulz T, Sauar J, Lygren I, Henriksen M, Stray N, Kjellevold Ø, Aadland E, Vatn M, Moum B (2005)
Course of disease, drug treatment and health-related quality of life in patients with inflammatory bowel disease 5 years after initial diagnosis
Eur J Gastroenterol Hepatol, 17 (10), 1037-45
DOI 10.1097/00042737-200510000-00006, PubMed 16148548

Bernklev T, Jahnsen J, Lygren I, Henriksen M, Vatn M, Moum B (2005)
Health-related quality of life in patients with inflammatory bowel disease measured with the short form-36: psychometric assessments and a comparison with general population norms
Inflamm Bowel Dis, 11 (10), 909-18
DOI 10.1097/01.mib.0000179467.01748.99, PubMed 16189421

Bernklev T, Jahnsen J, Aadland E, Sauar J, Schulz T, Lygren I, Henriksen M, Stray N, Kjellevold O, Vatn M, Moum B, IBSEN Study Group (2004)
Health-related quality of life in patients with inflammatory bowel disease five years after the initial diagnosis
Scand J Gastroenterol, 39 (4), 365-73
DOI 10.1080/00365520310008386, PubMed 15125469

Borthne AS, Dormagen JB, Gjesdal KI, Storaas T, Lygren I, Geitung JT (2002)
Bowel MR imaging with oral Gastrografin: an experimental study with healthy volunteers
Eur Radiol, 13 (1), 100-6
DOI 10.1007/s00330-002-1528-6, PubMed 12541116

van Bergeijk JD, Wilson JH, Nielsen OH, von Tirpitz C, Karvonen AL, Lygren I, Rädler A, Waldum HL, Mulder CJ, Friis S, Tefera S, Hoogkamer JF, OPUS 1 study group (2002)
Octreotide in patients with active ulcerative colitis treated with high dose corticosteroids (OPUS 1)
Eur J Gastroenterol Hepatol, 14 (3), 243-8
DOI 10.1097/00042737-200203000-00007, PubMed 11953688

Briseid K, Lygren I, Johannesen S, Marthinsen K (2000)
Removal of IgG from normal plasma and plasma from untreated patients with active Crohn's disease--effect on levels of contact factors
Scand J Clin Lab Invest, 60 (3), 237-45
DOI 10.1080/003655100750044893, PubMed 10885496

Lygren I, Andersen LP, Lerang F, Kleveland PM, Farup P, Vatn M, Aursnes I (1998)
[Treatment of Helicobacter pylori infection]
Tidsskr Nor Laegeforen, 118 (29), 4511-4
PubMed 9889634

Nilssen DE, Oktedalen O, Lygren I, Opstad PK, Brandtzaeg P (1998)
Intestinal IgA- and IgM-producing cells are not decreased in marathon runners
Int J Sports Med, 19 (6), 425-31
DOI 10.1055/s-2007-971940, PubMed 9774211

Moum B, Ekbom A, Vatn MH, Aadland E, Sauar J, Lygren I, Schulz T, Stray N, Fausa O (1997)
Clinical course during the 1st year after diagnosis in ulcerative colitis and Crohn's disease. Results of a large, prospective population-based study in southeastern Norway, 1990-93
Scand J Gastroenterol, 32 (10), 1005-12
DOI 10.3109/00365529709011217, PubMed 9361173

Moum B, Ekbom A, Vatn MH, Aadland E, Sauar J, Lygren I, Schulz T, Stray N, Fausa O (1997)
Inflammatory bowel disease: re-evaluation of the diagnosis in a prospective population based study in south eastern Norway
Gut, 40 (3), 328-32
DOI 10.1136/gut.40.3.328, PubMed 9135520

Aabakken L, Baasland I, Lygren I, Osnes M (1997)
Development and evaluation of written patient information for endoscopic procedures
Endoscopy, 29 (1), 23-6
DOI 10.1055/s-2007-1004056, PubMed 9083732

Moum B, Vatn MH, Ekbom A, Aadland E, Fausa O, Lygren I, Sauar J, Schulz T, Stray N (1996)
Incidence of ulcerative colitis and indeterminate colitis in four counties of southeastern Norway, 1990-93. A prospective population-based study. The Inflammatory Bowel South-Eastern Norway (IBSEN) Study Group of Gastroenterologists
Scand J Gastroenterol, 31 (4), 362-6
DOI 10.3109/00365529609006411, PubMed 8726304

Moum B, Vatn MH, Ekbom A, Aadland E, Fausa O, Lygren I, Stray N, Sauar J, Schulz T (1996)
Incidence of Crohn's disease in four counties in southeastern Norway, 1990-93. A prospective population-based study. The Inflammatory Bowel South-Eastern Norway (IBSEN) Study Group of Gastroenterologists
Scand J Gastroenterol, 31 (4), 355-61
DOI 10.3109/00365529609006410, PubMed 8726303

Moum B, Vatn MH, Ekbom A, Fausa O, Aadland E, Lygren I, Sauar J, Schulz T (1995)
Incidence of inflammatory bowel disease in southeastern Norway: evaluation of methods after 1 year of registration. Southeastern Norway IBD Study Group of Gastroenterologists
Digestion, 56 (5), 377-81
DOI 10.1159/000201262, PubMed 8549880

Jacobsen CD, Skjøtø J, Pytte R, Lygren I (1994)
[Follow-up of chronic inflammatory bowel disease. A 10-year material]
Tidsskr Nor Laegeforen, 114 (6), 674-7
PubMed 8191448

Aabakken L, Weberg R, Lygren I, Eidsvoll B, Stray N, Osnes M (1992)
Gastrointestinal bleeding associated with the use of non-steroidal, anti-inflammatory drugs--symptomatology and clinical course
Agents Actions, Spec No, C86-7
PubMed 1442342

AABAKKEN L, WEBERG R, LYGREN I, EIDSVOLL B, STRAY N, OSNES M (1992)
GASTROINTESTINAL-BLEEDING ASSOCIATED WITH THE USE OF NONSTEROIDAL, ANTIINFLAMMATORY DRUGS - SYMPTOMATOLOGY AND CLINICAL COURSE
Agents Actions, C86-C87

Aabakken L, Weberg R, Lygren I, Eidsvoll B, Stray N, Osnes M (1991)
Gastrointestinal bleeding: dyspeptic symptoms and clinical course in relation to use of non-steroidal antiinflammatory drugs
Scand J Rheumatol, 20 (5), 366-9
DOI 10.3109/03009749109096813, PubMed 1947900

Lygren I, Jacobsen CD, Rosseland AR, Trønnes S (1990)
[Endoscopic retrograde cholangio-pancreatography in suspected acute gallstone pancreatitis]
Tidsskr Nor Laegeforen, 110 (10), 1216-8
PubMed 2185580

Revhaug A, Lygren I, Jenssen TG, Giercksky KE, Burhol PG (1988)
Vasoactive intestinal peptide in sepsis and shock
Ann N Y Acad Sci, 527, 536-45
DOI 10.1111/j.1749-6632.1988.tb27007.x, PubMed 3291700

Gunnes P, Reikerås O, Lygren I (1986)
Secretin infusion in acute ischemic left ventricular failure: effects on myocardial performance and metabolism in a closed-chest dog model
J Pharmacol Exp Ther, 239 (3), 915-8
PubMed 3795050

Lygren I, Ostensen M, Burhol PG, Husby G (1986)
Gastrointestinal peptides in serum and synovial fluid from patients with inflammatory joint disease
Ann Rheum Dis, 45 (8), 637-40
DOI 10.1136/ard.45.8.637, PubMed 2874778

Waldum HL, Dregelid E, Larsen T, Lygren I, Burhol PG, Schulz TB (1986)
The effect of secretin on the abdominal distribution of the cardiac output using radiolabelled microspheres in rats
Mater Med Pol, 18 (1), 12-5
PubMed 3747604

Revhaug A, Lygren I, Lundgren TI, Jorde R, Andersen O, Burhol PG, Giercksky KE (1985)
Release of gastrointestinal hormones in cardiodepressive shock
Acta Anaesthesiol Scand, 29 (4), 371-4
DOI 10.1111/j.1399-6576.1985.tb02217.x, PubMed 2861702

Jenssen TG, Revhaug A, Burhol PG, Giercksky KE, Lygren I (1985)
The origin and fall of plasma motilin during Escherichia coli endotoxin shock in pigs
Acta Physiol Scand, 123 (4), 399-404
DOI 10.1111/j.1748-1716.1985.tb07606.x, PubMed 3887842

Revhaug A, Lygren I, Lundgren TI, Jorde R, Burhol PG, Giercksky KE (1985)
Changes in plasma levels of gastrointestinal regulatory peptides during hemorrhagic shock in pigs
Acta Chir Scand, 151 (5), 401-7
PubMed 2864773

Gunnes P, Smiseth OA, Lygren I, Jorde R (1985)
Effects of secretin infusion on myocardial performance and metabolism in the dog
J Cardiovasc Pharmacol, 7 (6), 1183-7
DOI 10.1097/00005344-198511000-00027, PubMed 2418308

Burhol PG, Jenssen TG, Schulz TB, Lygren I, Jorde R (1985)
Production and evaluation of rabbit cholecystokinin (CCK)
Mater Med Pol, 17 (1), 34-8
PubMed 4033220

Kaada B, Lygren I (1985)
Lower plasma levels of some gastrointestinal peptides in Raynaud's disease. Influence of transcutaneous nerve stimulation
Gen Pharmacol, 16 (2), 153-6
DOI 10.1016/0306-3623(85)90055-2, PubMed 3873378

Burhol PG, Lygren I, Jenssen TG, Jorde R (1985)
Diurnal profiles of plasma cholecystokinin (CCK) and vasoactive intestinal polypeptide (VIP) in man
Mater Med Pol, 17 (1), 30-3
PubMed 4040993

Revhaug A, Lygren I, Lundgren TI, Andersen OK, Burhol PG, Giercksky KE (1985)
Increased plasma levels of vasoactive intestinal polypeptide in pigs during endotoxinaemia
Eur Surg Res, 17 (2), 75-82
DOI 10.1159/000128451, PubMed 3884342

Lygren I, Revhaug A, Burhol PG, Giercksky KE (1984)
Portal and systemic plasma VIP and secretin during intravenous infusion of Escherichia coli endotoxin in pigs
Scand J Gastroenterol, 19 (8), 1048-52
PubMed 6398505

Jenssen TG, Burhol PG, Jorde R, Florholmen J, Lygren I (1984)
Radioimmunoassayable plasma motilin in man. Secretagogues, insulin-induced suppression, renal removal, and plasma components
Scand J Gastroenterol, 19 (6), 717-23
DOI 10.1080/00365521.1984.12005799, PubMed 6393315

Burhol PG, Lygren I, Jenssen TG, Florholmen J, Jorde R (1984)
Somatostatin release and plasma molecular somatostatin components in man
Acta Physiol Scand, 121 (3), 223-8
DOI 10.1111/j.1748-1716.1984.tb07450.x, PubMed 6433648

Lygren I, Revhaug A, Burhol PG, Giercksky KE, Jenssen TG (1984)
Vasoactive intestinal polypeptide and somatostatin in leucocytes
Scand J Clin Lab Invest, 44 (4), 347-51
DOI 10.3109/00365518409083818, PubMed 6147010

Giercksky KE, Gauperaa T, Andersen O, Revhaug A, Lygren I (1984)
Adjuvant therapy of secondary peritonitis
Scand J Gastroenterol Suppl, 100, 43-6
PubMed 6435238

Revhaug A, Lygren I, Lundgren TI, Jorde R, Burhol PG, Giercksky KE (1984)
Release of gastrointestinal peptides during E. coli endotoxinaemia
Acta Chir Scand, 150 (7), 535-9
PubMed 6151326

BURHOL PG, JENSSEN TG, JORDE R, LYGREN I, JOHNSON JA (1984)
PLASMA CHOLECYSTOKININ (CCK) BEFORE AND AFTER A JEJUNOILEAL BYPASS OPERATION IN OBESE PATIENTS WITH REFERENCE TO APPETITE REGULATION
Int. J. Obes., 8 (3), 233-236

Lygren I, Burhol PG, Waldum HL (1984)
Production and evaluation of VIP antibodies in rabbits
Mater Med Pol, 16 (1), 26-9
PubMed 6527569

Burhol PG, Jorde R, Jenssen TG, Lygren I, Florholmen J (1984)
Diurnal profile of plasma somatostatin in man
Acta Physiol Scand, 120 (1), 67-70
DOI 10.1111/j.1748-1716.1984.tb07374.x, PubMed 6144239

GIERCKSKY KE, GAUPERAA T, ANDERSEN O, REVHAUG A, LYGREN I (1984)
ADJUVANT THERAPY OF SECONDARY PERITONITIS
Scand. J. Gastroenterol., 19 100, 43-46

Burhol PG, Jenssen TG, Jorde R, Lygren I, Johnson JA (1984)
Plasma cholecystokinin (CCK) before and after a jejunoileal bypass operation in obese patients with reference to appetite regulation
Int J Obes, 8 (3), 233-6
PubMed 6746190

Bjorvatn B, Schultz TB, Haug BI, Lygren I, Gundersen SG (1983)
Mezlocillin treatment of septicemia in general hospitals
Scand J Infect Dis, 15 (1), 81-5
DOI 10.3109/inf.1983.15.issue-1.13, PubMed 6221403

Lygren I, Burhol PG, Jorde R, Waldum HL (1983)
The effect of insulin-induced hypoglycemia with and without atropine on plasma vasoactive intestinal polypeptide in man
Scand J Gastroenterol, 18 (1), 155-9
DOI 10.3109/00365528309181576, PubMed 6675173

Lygren I, Waldum HL, Burhol PG, Rekvig OP (1982)
Secretin exerts inhibition of the 8BrcAMP-stimulated 86Rb influx into avian red blood cells
Regul Pept, 4 (4), 221-5
DOI 10.1016/0167-0115(82)90114-8, PubMed 6293005

Lygren I, Jorde R, Burhol PG, Waldum HL (1982)
The effect of atropine on plasma vasoactive intestinal polypeptide after intraduodenal infusion of fat in man
Scand J Gastroenterol, 17 (3), 405-7
DOI 10.3109/00365528209182076, PubMed 7134868

Burhol PC, Jorde R, Lygren I, Waldum HL (1982)
[A review of gastrointestinal regulatory peptides]
Tidsskr Nor Laegeforen, 102 (3), 185-9
PubMed 7089943

Burhol PG, Jenssen TG, Lygren I, Schulz TB, Jorde R, Waldum HL (1982)
Iodination with Iodo-gen and radioimmunoassay of cholecystokinin (CCK) in acidified plasma, CCK release, and molecular CCK components in man
Digestion, 23 (3), 156-68
DOI 10.1159/000198723, PubMed 7106417

Jorde R, Waldum HL, Burhol PG, Lygren I, Schulz TB, Florholmen J, Jenssen TG (1981)
The effect of somatostatin on fasting and postprandial plasma GIP, serum insulin, and blood glucose in man
Scand J Gastroenterol, 16 (1), 113-9
PubMed 6112787

Jorde R, Burhol PG, Schulz TB, Waldum HL, Lygren I, Jenssen T, Myhre ES (1981)
The effect of a 34-h fast on the meal-induced rises in plasma GIP, serum insulin, and blood glucose in man
Scand J Gastroenterol, 16 (1), 109-12
PubMed 7015476

Burhol PG, Jorde R, Lygren I, Schulz TB, Waldum HL (1981)
Diurnal profile of plasma secretin in man
Digestion, 22 (4), 192-5
DOI 10.1159/000198644, PubMed 7198065

Vik T, Jorde R, Lygren I (1980)
[Indocyanine green clearance. A liver function test as sensitive as the bromsulphalein test?]
Tidsskr Nor Laegeforen, 100 (24), 1438-9
PubMed 7444890

Burhol PG, Lygren I, Waldum HL, Jorde R (1980)
The effect of duodenal infusion of bile on plasma VIP, GIP, and secretin and on duodenal bicarbonate secretion
Scand J Gastroenterol, 15 (8), 1007-11
DOI 10.3109/00365528009181805, PubMed 7233065

Lygren I, Burhol PG, Waldum HL, Jorde R (1980)
The effect of duodenal infusion of graded doses of HCL on plasma secretin and vasoactive intestinal polypeptide (VIP), and on duodenal bicarbonate secretion in man
Mater Med Pol, 12 (4), 223-8
PubMed 7266047

Jorde R, Burhol PG, Waldum HL, Schulz TB, Lygren I, Florholmen J (1980)
Diurnal variation of plasma gastric inhibitory polypeptide in man
Scand J Gastroenterol, 15 (5), 617-9
DOI 10.3109/00365528009182224, PubMed 7192431

Jorde R, Lygren I, Burhol PG, Waldum HL (1979)
The effect of intragastric infusion of bile, meat extract, CaCl2, and ethanol on plasma VIP and gastrin and on gastric H+ and pepsin outputs
Mater Med Pol, 11 (4), 330-3
PubMed 45275

Burhol PG, Waldum HL, Jorde R, Lygren I (1979)
The effect of a test meal on plasma vasoactive intestinal polypeptide (VIP), gastric inhibitory polypeptide (GIP), and secretin in man
Scand J Gastroenterol, 14 (8), 939-43
PubMed 531513

BURHOL PG, WALDUM HL, JORDE R, LYGREN I (1979)
EFFECT OF A TEST MEAL ON PLASMA VASOACTIVE INTESTINAL POLYPEPTIDE (VIP), GASTRIC-INHIBITORY POLYPEPTIDE (GIP), AND SECRETIN IN MAN
Scand. J. Gastroenterol., 14 (8), 939-943

Burhol PG, Lygren I, Waldum HL (1978)
Radioimmunoassay of vasoactive intestinal polypeptide in plasma
Scand J Gastroenterol, 13 (7), 807-13
DOI 10.3109/00365527809182195, PubMed 725503

Book chapters

Bernklev T, Jahnsen J, Aadland E, Sauar J, Schulz T, Lygren I, Henriksen M, Stray N, Kjellevold O, Vatn MH, Moum B (2004)
Health-related quality of life in patients with inflammatory bowel disease five years after the inital diagnosis
In Scandinavian journal of gastroenterology, Taylor & Francis, Basingstoke, 39(2004)4, s. 365-73
BIBSYS 051773643

Bernklev T, Henriksen M, Jahnsen J, Lygren I, Sauar J, Stary N, Kjellevold O, Aadland E, Vatn MH, Moum B (2003)
Health related quality of life five years after diagnosisin a prospective follow up study of patients with inflammatory bowel disease
In Gut, British Medical Association, London, 52(2003)suppl 6, s.A40
BIBSYS 041729900

Bernklev T, Jahnsen J, Henriksen M, Sauar J, Lygren I, Aadland E (2003)
Is a more severe course of inflammatory bowel disease reflected in the patients' health related quality of life 5 years after diagnosis in a prospective follow up study?
In Gut, British Medical Association, London, 52(2003)suppl 6, s.A207
BIBSYS 041731417

Theses

Lygren I (1985)
A study on vasoactive intestinal polypeptide (VIP)
[I. Lygren], Oslo, 1 b. (flere pag.)
BIBSYS 853133336